ACCESSWIRE
United States
Tel: 1-888-952-4446
Website: https://www.accesswire.com/
Email: DigitalSales@accesswire.com
About ACCESSWIRE
ACCESSWIRE is a global newswire and communications network, delivering regional, national and international news to thousands of customers across the world. ACCESSWIRE serves both public and private companies, disseminating their full-text and rich media press releases to news media, financial markets, investors, information websites, databases, bloggers and social networks.
The press release platform offers an exceptionally cost-effective Fair Disclosure, Regulation FD news dissemination and media outreach service.
Platform users can easily publish rich media assets, such as video, audio and images, and build their own distribution to the most-needed outlets. Users can effectively distribute an earnings announcement, product launch, community message, M&A transaction or corporate update to the worldwide news network.
Corporate issuers and their constituents find the cloud-based platforms and related services particularly robust — from document creation through dissemination to regulatory bodies, platforms and shareholders.
Contact ACCESSWIRE’s parent company, Issuer Direct, to learn more.
6066 articles about ACCESSWIRE
-
9 Meters Biopharma to Participate in the 2022 BIO International Convention
6/13/2022
9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced the Company's participation in the 2022 BIO International Convention on June 13 - 16, 2022, in San Diego, California.
-
Zomedica to Investigate Shock Wave Therapy of Exercised Induced Pulmonary Hemorrhage in Horses
6/13/2022
Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, has initiated a study to evaluate shock wave therapy as a treatment for Exercised Induced Pulmonary Hemorrhage.
-
Jaguar Health Announces Publication of Onco'Zine Article Underscoring the Importance of Controlling Diarrhea in Cancer Patients
6/13/2022
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that an article by Dr. Kathleen Kiernan Harnden titled Alleviating Targeted Therapy Side Effects: Essential for Patient QOL and Best Outcomes was published June 8, 2022 in Onco'Zine.
-
DiviTum®TKa Predicts Clinical Outcome of Patients in BioItaLEE Study
6/13/2022
Biovica announced that the company's blood test DiviTum®TKa was highlighted in an oral presentation on June 6th at the ASCO Annual Meeting from the BioItaLEE trial.
-
Today, the Subscription Period Begins in Spago Nanomedical's Rights Issue
6/13/2022
The subscription period begins in Spago Nanomedical AB's rights issue of shares of up to SEK 61.8 million, as resolved by the Board with the support of the authorization received at the Annual General Meeting on May 18, 2022.
-
Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea
6/13/2022
Dermata Therapeutics, Inc., a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, announced it has completed enrollment of its Phase 2 trial of DMT310 for the once-weekly treatment of moderate-to-severe rosacea.
-
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference
6/13/2022
Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the company will be participating in the Lytham Partners Summer 2022 Investor Conference taking place virtually on June 21-22, 2022.
-
Scientific Industries Integrates Important New Features into its VIVID Pill Counting Solution to Deliver Digitally Simplified Pharmacy Automation
6/10/2022
Scientific Industries, Inc., a life sciences tool provider, and a developer and provider of digitally simplified bioprocessing and pharmacy automation products, announced the release of its newly redesigned VIVID® automated pill counter.
-
NLS Pharmaceutics Announces Receipt of NASDAQ Minimum Bid Price Notification
6/10/2022
NLS Pharmaceutics Ltd. announces that it has received a written notice from Nasdaq Stock Market LLC, indicating that the Company is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550, which requires listed securities to maintain a minimum bid price of $1.00 per share.
-
Jaguar Health to Participate in BIO International Convention (BIO 2022)
6/10/2022
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Karen Brunke, PhD, the company's Executive Vice President of Corporate and Business Development, will be attending BIO 2022, taking place at the San Diego Convention Center from June 13 - 16, 2022.
-
Abivax Releases the Results of its June 9, 2022 Ordinary Annual and Extraordinary General Meeting
6/10/2022
Abivax SA held its ordinary annual and extraordinary general meeting of shareholders on June 9, 2022, which was chaired by Prof. Hartmut Ehrlich, M.D., CEO of Abivax, in the absence of the Chairman of the Board of directors.
-
Jaguar Health Reports Voting Results from 2022 Annual Meeting of Stockholders
6/10/2022
Jaguar Health, Inc. announced the voting results of the Company's 2022 Annual Meeting of Stockholders held on June 10, 2022.
-
Midatech Pharma PLC Announces Retirement of Chairman and Proposed New Chairman
6/10/2022
Midatech Pharma PLC, an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announces that Rolf Stahel, Chairman and non-executive director, intends to retire after the Company's Annual General Meeting on 20 June 2022.
-
Midatech Pharma PLC - MTX110 Study to be Presented at ISPNO 2022
6/10/2022
Midatech Pharma PLC is pleased to announce that investigators from Columbia University Irving Medical Center and New York-Presbyterian will present interim results from their ongoing Phase 1 study on Midatech's MTX110 in Diffuse Intrinsic Pontine Glioma at The International Symposium on Pediatric Neuro-Oncology that will take place on 12-15 June 2022 in Hamburg, Germany.
-
BioInvent Appoints Sylvie Ryckebusch as Chief Business Officer
6/9/2022
BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, announces the appointment of Sylvie Ryckebusch as Chief Business Officer.
-
IRLAB Strengthens Its Management Team by Appointing Richard Godfrey as New CEO and Nicholas Waters as Executive Vice President and Head of R&D
6/9/2022
IRLAB Therapeutics IRLAB announced that additional expertise is added to the company's management team to leverage opportunities arising from recent commercial and scientific successes.
-
Jaguar Health and Filament Health Sign Letter of Intent to Develop Botanical Prescription Drugs for Specific Mental Health Indications
6/9/2022
Jaguar Health, Inc. (NASDAQ:JAGX) and Filament Health Corp. (NEO:FH) today announced that the companies have signed a letter of intent to enter a collaboration agreement to develop botanical prescription drugs for specific psychoactive target indications in the United States.
-
Altamira Therapeutics Receives NASDAQ Notification Regarding Minimum Bid Requirements
6/9/2022
Altamira Therapeutics Ltd. announced that on June 02, 2022 the Company received a letter from the Listings Qualifications Department of the Nasdaq Stock Market LLC notifying the Company that the minimum bid price per share for its common shares was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550.
-
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
6/9/2022
Aptevo Therapeutics Inc. today announced new remission data on four additional patients.
-
Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition
6/9/2022
Sonnet BioTherapeutics Holdings, Inc. today announced data from a preclinical combination study of SON-1010 with a commercially available anti-PD1 compound.